RxDoctor Payments Data

Heather Ali, PA

Physician Assistant · Latham, NYNPI 1477596559

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 53 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$332
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$308
  • E.r. Squibb & Sons, L.L.C.$157
  • Novartis$141
  • Novo Nordisk$125
  • Actelion Pharmaceuticals US, Inc.$123
  • plus $210 from 5 others

What the payments were for

  • Food & beverage$1,31694%
  • Education$806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$25,393
Medicare patients
203
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$155,582
XareltoRivaroxaban36$50,910
EntrestoSacubitril/Valsartan20$27,864
BrilintaTicagrelor29$23,282
Praluent PenAlirocumab24$20,924
Repatha SureclickEvolocumab11$8,088
Dofetilide23$6,730
Ranolazine ErRanolazine20$3,803
Metoprolol Succinate163$2,834
Ezetimibe42$2,598
Rosuvastatin Calcium112$1,923
Nebivolol Hcl25$1,847
Atorvastatin Calcium137$1,837
Nifedipine ErNifedipine32$871
Carvedilol65$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$52$50,91036 claims
NovartisEntresto$141$27,86420 claims
AstraZenecaBrilinta$332$23,28229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Latham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →